promising biotech, page-4

it is an exceptional risk / return tradeoff at these prices.

i expect that Cephalon will exercise the options . . . . .and if it does so it will also bid for the company. It's just not much fun being a 28% shareholder. . . . .

NOTE - UBS out of NEW YORK did a piece on OMAPRO about three weeks ago. they reckon it could generate $1 a share in EPS accretion for CEPHALON in 2014/2015

NOW. . . . .why would they write the report unless Cephalon was giving them the nudge that OMAPRO is very much in their planning. . . ..

note that if we assume that the data is handed over on the last day of March, then exercise data for the options is about the end of the first week of april. THAT IS THE LATEST DATE FOR NEWS. . . . .